Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice

Faiez Zannad, Wendy Gattis Stough, Patrick Rossignol, Johann Bauersachs, John J V McMurray, Karl Swedberg, Allan D. Struthers, Adriaan A. Voors, Luis M. Ruilope, George L. Bakris, Christopher M. O'Connor, Mihai Gheorghiade, Robert J. Mentz, Alain Cohen-Solal, Aldo P. Maggioni, Farzin Beygui, Gerasimos S. Filippatos, Ziad A. Massy, Atul Pathak, Ileana L. PinaHani N. Sabbah, Domenic A. Sica, Luigi Tavazzi, Bertram Pitt

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. These clinical benefits are observed in addition to those of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers. The morbidity and mortality benefits of MRAs may be mediated by several proposed actions, including antifibrotic mechanisms that slow heart failure progression, prevent or reverse cardiac remodelling, or reduce arrhythmogenesis. Both eplerenone and spironolactone have demonstrated survival benefits in individual clinical trials. Pharmacologic differences exist between the drugs, which may be relevant for therapeutic decision making in individual patients. Although serious hyperkalaemia events were reported in the major MRA clinical trials, these risks can be mitigated through appropriate patient selection, dose selection, patient education, monitoring, and follow-up. When used appropriately, MRAs significantly improve outcomes across the spectrum of patients with HF-REF.

Original languageEnglish (US)
Pages (from-to)2782-2795
Number of pages14
JournalEuropean Heart Journal
Volume33
Issue number22
DOIs
StatePublished - Nov 2012

Fingerprint

Mineralocorticoid Receptor Antagonists
Heart Failure
Clinical Trials
Systolic Heart Failure
Morbidity
Spironolactone
Hyperkalemia
Survival
Angiotensin Receptor Antagonists
Physiologic Monitoring
Left Ventricular Dysfunction
Patient Education
Angiotensin-Converting Enzyme Inhibitors
Patient Selection
Decision Making
Myocardial Infarction
Mortality
Pharmaceutical Preparations

Keywords

  • Aldosterone antagonist spironolactone
  • Heart failure
  • Mineralocorticoid receptors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Zannad, F., Gattis Stough, W., Rossignol, P., Bauersachs, J., McMurray, J. J. V., Swedberg, K., ... Pitt, B. (2012). Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice. European Heart Journal, 33(22), 2782-2795. https://doi.org/10.1093/eurheartj/ehs257

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction : Integrating evidence into clinical practice. / Zannad, Faiez; Gattis Stough, Wendy; Rossignol, Patrick; Bauersachs, Johann; McMurray, John J V; Swedberg, Karl; Struthers, Allan D.; Voors, Adriaan A.; Ruilope, Luis M.; Bakris, George L.; O'Connor, Christopher M.; Gheorghiade, Mihai; Mentz, Robert J.; Cohen-Solal, Alain; Maggioni, Aldo P.; Beygui, Farzin; Filippatos, Gerasimos S.; Massy, Ziad A.; Pathak, Atul; Pina, Ileana L.; Sabbah, Hani N.; Sica, Domenic A.; Tavazzi, Luigi; Pitt, Bertram.

In: European Heart Journal, Vol. 33, No. 22, 11.2012, p. 2782-2795.

Research output: Contribution to journalArticle

Zannad, F, Gattis Stough, W, Rossignol, P, Bauersachs, J, McMurray, JJV, Swedberg, K, Struthers, AD, Voors, AA, Ruilope, LM, Bakris, GL, O'Connor, CM, Gheorghiade, M, Mentz, RJ, Cohen-Solal, A, Maggioni, AP, Beygui, F, Filippatos, GS, Massy, ZA, Pathak, A, Pina, IL, Sabbah, HN, Sica, DA, Tavazzi, L & Pitt, B 2012, 'Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice', European Heart Journal, vol. 33, no. 22, pp. 2782-2795. https://doi.org/10.1093/eurheartj/ehs257
Zannad, Faiez ; Gattis Stough, Wendy ; Rossignol, Patrick ; Bauersachs, Johann ; McMurray, John J V ; Swedberg, Karl ; Struthers, Allan D. ; Voors, Adriaan A. ; Ruilope, Luis M. ; Bakris, George L. ; O'Connor, Christopher M. ; Gheorghiade, Mihai ; Mentz, Robert J. ; Cohen-Solal, Alain ; Maggioni, Aldo P. ; Beygui, Farzin ; Filippatos, Gerasimos S. ; Massy, Ziad A. ; Pathak, Atul ; Pina, Ileana L. ; Sabbah, Hani N. ; Sica, Domenic A. ; Tavazzi, Luigi ; Pitt, Bertram. / Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction : Integrating evidence into clinical practice. In: European Heart Journal. 2012 ; Vol. 33, No. 22. pp. 2782-2795.
@article{309647ba48d7451f8744a171ea5bd9de,
title = "Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice",
abstract = "Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. These clinical benefits are observed in addition to those of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers. The morbidity and mortality benefits of MRAs may be mediated by several proposed actions, including antifibrotic mechanisms that slow heart failure progression, prevent or reverse cardiac remodelling, or reduce arrhythmogenesis. Both eplerenone and spironolactone have demonstrated survival benefits in individual clinical trials. Pharmacologic differences exist between the drugs, which may be relevant for therapeutic decision making in individual patients. Although serious hyperkalaemia events were reported in the major MRA clinical trials, these risks can be mitigated through appropriate patient selection, dose selection, patient education, monitoring, and follow-up. When used appropriately, MRAs significantly improve outcomes across the spectrum of patients with HF-REF.",
keywords = "Aldosterone antagonist spironolactone, Heart failure, Mineralocorticoid receptors",
author = "Faiez Zannad and {Gattis Stough}, Wendy and Patrick Rossignol and Johann Bauersachs and McMurray, {John J V} and Karl Swedberg and Struthers, {Allan D.} and Voors, {Adriaan A.} and Ruilope, {Luis M.} and Bakris, {George L.} and O'Connor, {Christopher M.} and Mihai Gheorghiade and Mentz, {Robert J.} and Alain Cohen-Solal and Maggioni, {Aldo P.} and Farzin Beygui and Filippatos, {Gerasimos S.} and Massy, {Ziad A.} and Atul Pathak and Pina, {Ileana L.} and Sabbah, {Hani N.} and Sica, {Domenic A.} and Luigi Tavazzi and Bertram Pitt",
year = "2012",
month = "11",
doi = "10.1093/eurheartj/ehs257",
language = "English (US)",
volume = "33",
pages = "2782--2795",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "22",

}

TY - JOUR

T1 - Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction

T2 - Integrating evidence into clinical practice

AU - Zannad, Faiez

AU - Gattis Stough, Wendy

AU - Rossignol, Patrick

AU - Bauersachs, Johann

AU - McMurray, John J V

AU - Swedberg, Karl

AU - Struthers, Allan D.

AU - Voors, Adriaan A.

AU - Ruilope, Luis M.

AU - Bakris, George L.

AU - O'Connor, Christopher M.

AU - Gheorghiade, Mihai

AU - Mentz, Robert J.

AU - Cohen-Solal, Alain

AU - Maggioni, Aldo P.

AU - Beygui, Farzin

AU - Filippatos, Gerasimos S.

AU - Massy, Ziad A.

AU - Pathak, Atul

AU - Pina, Ileana L.

AU - Sabbah, Hani N.

AU - Sica, Domenic A.

AU - Tavazzi, Luigi

AU - Pitt, Bertram

PY - 2012/11

Y1 - 2012/11

N2 - Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. These clinical benefits are observed in addition to those of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers. The morbidity and mortality benefits of MRAs may be mediated by several proposed actions, including antifibrotic mechanisms that slow heart failure progression, prevent or reverse cardiac remodelling, or reduce arrhythmogenesis. Both eplerenone and spironolactone have demonstrated survival benefits in individual clinical trials. Pharmacologic differences exist between the drugs, which may be relevant for therapeutic decision making in individual patients. Although serious hyperkalaemia events were reported in the major MRA clinical trials, these risks can be mitigated through appropriate patient selection, dose selection, patient education, monitoring, and follow-up. When used appropriately, MRAs significantly improve outcomes across the spectrum of patients with HF-REF.

AB - Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. These clinical benefits are observed in addition to those of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers. The morbidity and mortality benefits of MRAs may be mediated by several proposed actions, including antifibrotic mechanisms that slow heart failure progression, prevent or reverse cardiac remodelling, or reduce arrhythmogenesis. Both eplerenone and spironolactone have demonstrated survival benefits in individual clinical trials. Pharmacologic differences exist between the drugs, which may be relevant for therapeutic decision making in individual patients. Although serious hyperkalaemia events were reported in the major MRA clinical trials, these risks can be mitigated through appropriate patient selection, dose selection, patient education, monitoring, and follow-up. When used appropriately, MRAs significantly improve outcomes across the spectrum of patients with HF-REF.

KW - Aldosterone antagonist spironolactone

KW - Heart failure

KW - Mineralocorticoid receptors

UR - http://www.scopus.com/inward/record.url?scp=84869417804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869417804&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehs257

DO - 10.1093/eurheartj/ehs257

M3 - Article

C2 - 22942339

AN - SCOPUS:84869417804

VL - 33

SP - 2782

EP - 2795

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 22

ER -